文献速递眼底病与葡萄膜炎

常见抗炎药物与2型糖尿病中威胁视力糖尿病视网膜病变风险降低相关

Association of Common Anti-Inflammatory Medications with Reduced Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes.
PubMed 文献 · Ophthalmology · 2026-09-10

该回顾性倾向评分匹配队列研究纳入TriNetX美国协作网络中2型糖尿病成人,比较使用西替利嗪、布洛芬、泼尼松、非诺贝特或加巴喷丁者与未使用者3年内糖尿病黄斑水肿(DME)和增殖性糖尿病视网膜病变(PDR)的发生率。结果显示西替利嗪、布洛芬、泼尼松均与DME和PDR发生率降低相关,效应量与阳性对照非诺贝特相近,加巴喷丁无关联;9项敏感性分析结果一致。

要点

  • 西替利嗪、布洛芬、泼尼松均与2型糖尿病成人3年内DME和PDR发生率降低相关。
  • 泼尼松关联的效应量最大,DME HR 0.46、PDR HR 0.36;非诺贝特阳性对照效应量相近。
  • 加巴喷丁阴性对照无关联(DME HR 0.95,PDR HR 1.04),9项敏感性分析结果一致。

核心结论

  • 西替利嗪、布洛芬和泼尼松与2型糖尿病成人DME和PDR发生率降低相关,效应量与非诺贝特阳性对照相当。
  • 研究结果支持对抗炎药物预防威胁视力糖尿病视网膜病变进行前瞻性评估。

研究设计与样本

  • 回顾性倾向评分匹配队列研究,数据来自TriNetX美国协作网络。
  • 纳入2005年1月1日至2025年3月1日期间有2次记录使用西替利嗪、布洛芬、泼尼松、非诺贝特或加巴喷丁且接受眼科诊疗的2型糖尿病成人。

主要发现

  • 西替利嗪与DME降低相关(HR 0.62;95%CI 0.51-0.74),与PDR降低相关(HR 0.59;95%CI 0.46-0.77)。
  • 布洛芬与DME降低相关(HR 0.63;95%CI 0.56-0.69),与PDR降低相关(HR 0.48;95%CI 0.41-0.56)。
  • 泼尼松与DME降低相关(HR 0.46;95%CI 0.41-0.52),与PDR降低相关(HR 0.36;95%CI 0.30-0.43)。
  • 非诺贝特阳性对照显示相近效应量(DME HR 0.57;95%CI 0.48-0.68;PDR HR 0.59;95%CI 0.45-0.77)。
  • 加巴喷丁阴性对照无关联(DME HR 0.95;95%CI 0.88-1.02;PDR HR 1.04;95%CI 0.93-1.15)。

关键数值与推荐

  • 主要结局为索引日期后3年内新发DME和PDR。
  • 研究药物点E值为2.57至4.97(95%CI下限1.93至4.06)。
  • 8项眼科阴性对照结局对西替利嗪和布洛芬接近无效,对泼尼松和非诺贝特显示轻度保护性偏倚。

临床怎么用

  • 提示西替利嗪、布洛芬、泼尼松等常见抗炎药物可能与降低DME和PDR风险相关,但当前为回顾性关联证据。
  • 目前不应仅基于该研究改变糖尿病视网膜病变的预防用药,需等待前瞻性研究验证。

局限性

  • 为回顾性队列研究,尽管采用倾向评分匹配、阴性对照结局和E值分析,仍可能存在残余混杂。
  • 泼尼松和非诺贝特的阴性对照结局分析显示轻度保护性偏倚。
  • 结论需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether adults with type 2 diabetes mellitus (T2DM) using cetirizine, ibuprofen, or prednisone have a reduced incidence of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). DESIGN: Retrospective propensity score-matched cohort study. PARTICIPANTS: Adults with T2DM and documented eye care in the TriNetX US Collaborative Network who had 2 documented uses of cetirizine, ibuprofen, prednisone, fenofibrate, or gabapentin between January 1, 2005, and March 1, 2025. METHODS: Each drug cohort was 1:1 propensity score-matched on 44 covariates against nonusers; fenofibrate served as a positive control, and gabapentin served as both a negative control and an active comparator. Residual confounding was assessed using 8 ophthalmic negative-control outcomes (NCOs) and E values. Nine sensitivity analyses tested comparisons with users of gabapentin, alternative outcome windows, a new-user design, glycemic strata, matching for drug indication, and exposure duration. MAIN OUTCOME MEASURES: Incident DME and PDR within 3 years of the index date. RESULTS: Matched-pair counts ranged from 18 762 to 86 846. Cetirizine was associated with reduced DME (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.51-0.74) and PDR (HR, 0.59; 95% CI, 0.46-0.77); ibuprofen with reduced DME (HR, 0.63; 95% CI, 0.56-0.69) and PDR (HR, 0.48; 95% CI, 0.41-0.56); and prednisone with reduced DME (HR, 0.46; 95% CI, 0.41-0.52) and PDR (HR, 0.36; 95% CI, 0.30-0.43). Fenofibrate showed associations of similar magnitude (DME HR, 0.57; 95% CI, 0.48-0.68; PDR HR, 0.59; 95% CI, 0.45-0.77); gabapentin showed no association (DME HR, 0.95; 95% CI, 0.88-1.02; PDR HR, 1.04; 95% CI, 0.93-1.15). Point E values for the investigational drugs ranged from 2.57 to 4.97 (lower 95% CI bound, 1.93-4.06). The NCO panel was near null for cetirizine and ibuprofen and showed mild protective bias for prednisone and fenofibrate. Findings persisted across the 9 sensitivity analyses. CONCLUSIONS: Cetirizine, ibuprofen, and prednisone were associated with reduced incidence of DME and PDR in adults with T2DM, with effect sizes comparable to those of the fenofibrate positive control. These findings support prospective evaluation of anti-inflammatory medications for the prevention of vision-threatening diabetic retinopathy. FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Bison HS, Zhu AS, Borissov M, et al. Association of Common Anti-Inflammatory Medications with Reduced Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes. Ophthalmology. 2026. PMID: 42722111. doi:10.1016/j.ophtha.2026.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。